Envista Holdings Corporation (NYSE:NVST – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the seventeen brokerages that are covering the firm, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $29.8571.
NVST has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft set a $32.00 price target on shares of Envista in a research note on Thursday, September 3rd. Wall Street Zen downgraded Envista from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 5th. Mizuho set a $29.00 price target on Envista in a research note on Thursday, August 6th. BMO Capital Markets reissued a “market perform” rating on shares of Envista in a report on Thursday, September 10th. Finally, Robert W. Baird set a $34.00 price objective on Envista in a research note on Thursday, August 6th.
Check Out Our Latest Stock Report on NVST
Envista Stock Up 3.3%
Envista (NYSE:NVST – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.07. The company had revenue of $730.50 million for the quarter, compared to analyst estimates of $716.11 million. Envista had a net margin of 3.33% and a return on equity of 7.88%. The business’s quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.26 earnings per share. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. As a group, sell-side analysts predict that Envista will post 1.53 EPS for the current fiscal year.
Insider Activity at Envista
In other news, SVP Mischa Reis sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total transaction of $220,000.00. Following the completion of the sale, the senior vice president owned 27,321 shares of the company’s stock, valued at approximately $751,327.50. This trade represents a 22.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.99% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Tidal Investments LLC grew its holdings in Envista by 2.4% during the 2nd quarter. Tidal Investments LLC now owns 23,555 shares of the company’s stock worth $621,000 after acquiring an additional 547 shares in the last quarter. WINTON GROUP Ltd raised its stake in shares of Envista by 247.9% in the 2nd quarter. WINTON GROUP Ltd now owns 192,055 shares of the company’s stock valued at $5,061,000 after purchasing an additional 136,855 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Envista in the 2nd quarter valued at about $210,000. Squarepoint Ops LLC bought a new position in shares of Envista during the second quarter worth about $1,464,000. Finally, Allworth Financial LP lifted its position in shares of Envista by 56.1% during the second quarter. Allworth Financial LP now owns 3,441 shares of the company’s stock worth $91,000 after purchasing an additional 1,237 shares during the last quarter.
Envista Company Profile
Envista Holdings Corporation is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral-care professionals.
Envista’s portfolio includes dental imaging and diagnostic systems, digital dentistry and CAD/CAM solutions, dental implants, orthodontic brackets and wires, clear aligner products, endodontic instruments, restorative materials, infection-prevention products and other dental consumables.
Featured Stories
- Five stocks we like better than Envista
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
